Assessing the efficacy of gene therapy in Rpe65-/- mice using photoentrainment of circadian rhythm

Chris W. Stoddart; Meaghan J.T. Yu; Matthew T. Martin-Iverson; Dru M. Daniels; C. May Lai; Nigel L. Barnett; T. Michael Redmond; Kristina Narfström; P. Elizabeth Rakoczy

doi:10.1007/0-387-32442-9_34

Assessing the efficacy of gene therapy in Rpe65^-/- mice using photoentrainment of circadian rhythm

Chris W. Stoddart, Meaghan J.T. Yu, Matthew T. Martin-Iverson, Dru M. Daniels, C. May Lai, Nigel L. Barnett, T. Michael Redmond, Kristina Narfström, P. Elizabeth Rakoczy^*

^*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceeding › Chapter › Research › peer-review

2 Citations (Scopus)

Abstract

Gene therapy (GT) can be described as the in vivo transfer of DNA for therapeutic purposes. In the case of congenital retinal dystrophies (RD), GT can only be considered a successful treatment option if the gene transfer results in the restoration of vision at some level. Thus, a critical component of developing GT treatments for RDs is assessing the amount of functioning vision that is produced. In mouse models of RD, visual function after gene therapy is tested using techniques such as electroretinograms (ERGs) and retinoid analysis. A potentially useful addition to these tests would be a murine behavior-based technique, like those used with the RPE65 dog model, to demonstrate effective GT-induced visual recovery.

Original language	English
Title of host publication	Retinal Degenerative Diseases
Editors	Joe G. Hollyfield, Robert E. Anderson, Matthew M. LaVail
Place of Publication	Boston
Publisher	Springer
Chapter	34
Pages	239-245
Number of pages	7
ISBN (Electronic)	978-0-387-32442-5
ISBN (Print)	978-0387-28464-4
DOIs	https://doi.org/10.1007/0-387-32442-9_34
Publication status	Published - 2006
Externally published	Yes

Publication series

Name	Advances in Experimental Medicine and Biology
Publisher	Springer
Volume	572
ISSN (Print)	0065-2598

Access to Document

10.1007/0-387-32442-9_34

Cite this

Stoddart, C. W., Yu, M. J. T., Martin-Iverson, M. T., Daniels, D. M., Lai, C. M., Barnett, N. L., Redmond, T. M., Narfström, K., & Rakoczy, P. E. (2006). Assessing the efficacy of gene therapy in Rpe65^-/- mice using photoentrainment of circadian rhythm. In J. G. Hollyfield, R. E. Anderson, & M. M. LaVail (Eds.), Retinal Degenerative Diseases (pp. 239-245). (Advances in Experimental Medicine and Biology; Vol. 572). Springer. https://doi.org/10.1007/0-387-32442-9_34

@inbook{8f55a206b90641d7a1cd9335446e2415,

title = "Assessing the efficacy of gene therapy in Rpe65-/- mice using photoentrainment of circadian rhythm",

abstract = "Gene therapy (GT) can be described as the in vivo transfer of DNA for therapeutic purposes. In the case of congenital retinal dystrophies (RD), GT can only be considered a successful treatment option if the gene transfer results in the restoration of vision at some level. Thus, a critical component of developing GT treatments for RDs is assessing the amount of functioning vision that is produced. In mouse models of RD, visual function after gene therapy is tested using techniques such as electroretinograms (ERGs) and retinoid analysis. A potentially useful addition to these tests would be a murine behavior-based technique, like those used with the RPE65 dog model, to demonstrate effective GT-induced visual recovery.",

author = "Stoddart, {Chris W.} and Yu, {Meaghan J.T.} and Martin-Iverson, {Matthew T.} and Daniels, {Dru M.} and Lai, {C. May} and Barnett, {Nigel L.} and Redmond, {T. Michael} and Kristina Narfstr{\"o}m and Rakoczy, {P. Elizabeth}",

year = "2006",

doi = "10.1007/0-387-32442-9_34",

language = "English",

isbn = "978-0387-28464-4",

series = "Advances in Experimental Medicine and Biology",

publisher = "Springer",

pages = "239--245",

editor = "Hollyfield, {Joe G.} and Anderson, {Robert E.} and LaVail, {Matthew M.}",

booktitle = "Retinal Degenerative Diseases",

address = "Germany",

}

Stoddart, CW, Yu, MJT, Martin-Iverson, MT, Daniels, DM, Lai, CM, Barnett, NL, Redmond, TM, Narfström, K & Rakoczy, PE 2006, Assessing the efficacy of gene therapy in Rpe65^-/- mice using photoentrainment of circadian rhythm. in JG Hollyfield, RE Anderson & MM LaVail (eds), Retinal Degenerative Diseases. Advances in Experimental Medicine and Biology, vol. 572, Springer, Boston, pp. 239-245. https://doi.org/10.1007/0-387-32442-9_34

Assessing the efficacy of gene therapy in Rpe65^-/- mice using photoentrainment of circadian rhythm. / Stoddart, Chris W.; Yu, Meaghan J.T.; Martin-Iverson, Matthew T. et al.
Retinal Degenerative Diseases. ed. / Joe G. Hollyfield; Robert E. Anderson; Matthew M. LaVail. Boston: Springer, 2006. p. 239-245 (Advances in Experimental Medicine and Biology; Vol. 572).

Research output: Chapter in Book/Report/Conference proceeding › Chapter › Research › peer-review

TY - CHAP

T1 - Assessing the efficacy of gene therapy in Rpe65-/- mice using photoentrainment of circadian rhythm

AU - Stoddart, Chris W.

AU - Yu, Meaghan J.T.

AU - Martin-Iverson, Matthew T.

AU - Daniels, Dru M.

AU - Lai, C. May

AU - Barnett, Nigel L.

AU - Redmond, T. Michael

AU - Narfström, Kristina

AU - Rakoczy, P. Elizabeth

PY - 2006

Y1 - 2006

N2 - Gene therapy (GT) can be described as the in vivo transfer of DNA for therapeutic purposes. In the case of congenital retinal dystrophies (RD), GT can only be considered a successful treatment option if the gene transfer results in the restoration of vision at some level. Thus, a critical component of developing GT treatments for RDs is assessing the amount of functioning vision that is produced. In mouse models of RD, visual function after gene therapy is tested using techniques such as electroretinograms (ERGs) and retinoid analysis. A potentially useful addition to these tests would be a murine behavior-based technique, like those used with the RPE65 dog model, to demonstrate effective GT-induced visual recovery.

AB - Gene therapy (GT) can be described as the in vivo transfer of DNA for therapeutic purposes. In the case of congenital retinal dystrophies (RD), GT can only be considered a successful treatment option if the gene transfer results in the restoration of vision at some level. Thus, a critical component of developing GT treatments for RDs is assessing the amount of functioning vision that is produced. In mouse models of RD, visual function after gene therapy is tested using techniques such as electroretinograms (ERGs) and retinoid analysis. A potentially useful addition to these tests would be a murine behavior-based technique, like those used with the RPE65 dog model, to demonstrate effective GT-induced visual recovery.

UR - http://www.scopus.com/inward/record.url?scp=33747430132&partnerID=8YFLogxK

UR - https://link.springer.com/book/10.1007/0-387-32442-9

U2 - 10.1007/0-387-32442-9_34

DO - 10.1007/0-387-32442-9_34

M3 - Chapter

C2 - 17249580

AN - SCOPUS:33747430132

SN - 978-0387-28464-4

T3 - Advances in Experimental Medicine and Biology

SP - 239

EP - 245

BT - Retinal Degenerative Diseases

A2 - Hollyfield, Joe G.

A2 - Anderson, Robert E.

A2 - LaVail, Matthew M.

PB - Springer

CY - Boston

ER -

Stoddart CW, Yu MJT, Martin-Iverson MT, Daniels DM, Lai CM, Barnett NL et al. Assessing the efficacy of gene therapy in Rpe65^-/- mice using photoentrainment of circadian rhythm. In Hollyfield JG, Anderson RE, LaVail MM, editors, Retinal Degenerative Diseases. Boston: Springer. 2006. p. 239-245. (Advances in Experimental Medicine and Biology). doi: 10.1007/0-387-32442-9_34

Assessing the efficacy of gene therapy in Rpe65^-/- mice using photoentrainment of circadian rhythm

Abstract

Publication series

Access to Document

Other files and links

Fingerprint

Glutamate transport modulation: A possible role in retinal neuroprotection

Cite this

Assessing the efficacy of gene therapy in Rpe65-/- mice using photoentrainment of circadian rhythm

Abstract

Publication series

Access to Document

Other files and links

Fingerprint

Related Research Outputs

Glutamate transport modulation: A possible role in retinal neuroprotection

Cite this

Assessing the efficacy of gene therapy in Rpe65^-/- mice using photoentrainment of circadian rhythm